BioPorto (BIOPOR) Strategy update summary

Strategic plan and market access

• Launched the "Forward" plan, a three-year strategy to expand kidney care market access, targeting over 100 global hospitals by 2027 and 170+ by 2028, with a focus on both adult and pediatric indications.

• Preparing for guideline updates and expanding instrument partnerships with major diagnostic companies to accelerate adoption in laboratories.

• Ongoing adult clinical study with FDA and IVDR clearance expected in 2027, supporting expansion into new patient segments and clinical settings.

Commercialization and operational execution

• Emphasis on pediatric market while preparing for adult entry in the US and EU, leveraging US experience for targeted European expansion.

• Direct and indirect sales strategies, clinical education, and operational support are being implemented to drive adoption.

• US hospital adoption is increasing, supported by research use and FDA clearance for pediatric use.

Financial performance and guidance

• Q3 2025 revenue reached DKK 10.4 million, a 7% increase year-over-year (10% at constant exchange rates).

• Adjusted EBITDA loss for Q3 2025 was DKK (16.8) million, a 14% improvement from Q3 2024.

• Cash position at end of Q3 2025 was DKK 27.6 million.

• Revised 2025 revenue guidance lowered to DKK 40-45 million, with adjusted EBITDA loss unchanged at DKK 75-80 million.